Breakdown | ||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.38M | 299.23K | 292.36K | 8.83K | 0.00 | Gross Profit |
-17.08M | -21.31M | -3.00M | -2.97M | 0.00 | EBIT |
-38.90M | -36.62M | -40.29M | -23.93M | -484.75K | EBITDA |
-36.53M | -45.38M | -31.19M | -18.04M | -484.75K | Net Income Common Stockholders |
-41.92M | -47.95M | -34.61M | -30.34M | -485.19K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
32.59M | 18.58M | 11.70M | 26.98M | 27.09K | Total Assets |
91.05M | 72.04M | 74.95M | 83.38M | 33.44K | Total Debt |
0.00 | 0.00 | 0.00 | 0.00 | 59.00K | Net Debt |
-32.59M | -18.58M | -11.70M | -26.98M | 31.91K | Total Liabilities |
17.63M | 44.68M | 29.37M | 20.42M | 158.14K | Stockholders Equity |
73.42M | 28.12M | 44.38M | 62.96M | -124.70K |
Cash Flow | Free Cash Flow | |||
-33.42M | -22.98M | -24.73M | -38.25M | -32.91K | Operating Cash Flow |
-33.42M | -22.98M | -23.20M | -9.91M | -32.91K | Investing Cash Flow |
3.00M | 0.00 | -1.53M | -28.37M | 0.00 | Financing Cash Flow |
64.51M | 29.88M | 9.22M | 65.11M | 60.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | AU$205.88M | ― | -37.20% | ― | ― | 32.02% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
53 Neutral | AU$699.91M | ― | -112.97% | ― | ― | -84.82% | |
41 Neutral | $119.47M | ― | -99.05% | ― | ― | -34.09% | |
36 Underperform | AU$3.32M | ― | -119.28% | ― | ― | 64.10% | |
34 Underperform | AU$58.35M | ― | -108.26% | ― | ― | 53.41% | |
30 Underperform | $738.77M | ― | ― | -24.46% | -7.90% |
Radiopharm Theranostics Limited announced significant advancements in its clinical trials and shareholder structure. Lantheus Holdings Inc. increased its stake to 12.16% through a US$5 million placement, providing funds to advance Radiopharm’s clinical pipeline. The company reported successful detection of brain metastases using RAD 101, a novel imaging agent, and positive preclinical data for RAD202, a HER2-targeting radiopharmaceutical. These developments underscore Radiopharm’s potential to improve cancer diagnostics and treatment, positioning it as a key player in the radiopharmaceutical industry.
Radiopharm Theranostics has commenced dosing the first patient in a U.S. Phase 2b imaging study using 18F-RAD101 for suspected recurrent brain metastasis. This trial aims to evaluate the diagnostic performance of 18F-RAD101, a novel imaging small molecule targeting fatty acid synthase, in patients with confirmed recurrent brain metastases. The study’s primary objective is to assess the concordance between 18F-RAD101 positive lesions and conventional MRI imaging. The trial underscores Radiopharm’s commitment to advancing diagnostic precision in oncology, potentially improving treatment decisions for over 300,000 patients diagnosed with brain metastasis annually in the U.S.
Radiopharm Theranostics Limited has announced positive data from studies on its RAD202 product, presented at the European Molecular Imaging Meeting 2025. The data highlights the specific tumor targeting and favorable biodistribution of 68Ga-RAD202 for imaging, and the efficacy of 177Lu-RAD202 in reducing tumor volume and extending survival in HER2-positive solid tumors. These findings support ongoing clinical trials and suggest potential benefits for patients with advanced HER2-positive cancers, positioning the company as a leader in addressing unmet needs in oncology.
Radiopharm Theranostics Limited reported a 20.90% decrease in its loss from ordinary activities after tax for the half-year ended December 31, 2024, amounting to $18,725,453. Despite the reduction in losses, the company did not declare any dividends for the current or previous financial periods, and there were no changes in controlled entities. The financial statements were reviewed by an independent auditor, who issued an unmodified opinion, reflecting stability in the company’s financial reporting.
Radiopharm Theranostics Limited announced its participation in the TD Cowen Annual Healthcare Conference in Boston, where CEO Riccardo Canevari will present the company’s investment proposition. This presentation is a strategic move to attract investor interest, showcasing Radiopharm’s world-class pipeline and potential market leadership in radiopharmaceuticals, particularly in areas with high unmet medical needs.
Radiopharm Theranostics Limited announced its participation in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York on 28 February 2025. This event will feature over 35 biopharma and med-tech companies, providing Radiopharm an opportunity to present its innovative oncology solutions to a mix of institutional and professional investors, potentially enhancing its industry positioning and stakeholder engagement.
Radiopharm Theranostics Limited has announced successful clinical trial data showcasing the effectiveness of RAD 101 (18F-Pivalate) in detecting brain metastases using a novel PET-mpMRI imaging approach. This breakthrough demonstrates a high tumor-to-background ratio, promising a more sensitive detection method compared to the current standard of care, and could significantly improve diagnostic accuracy for suspected recurrent brain metastases. The ongoing Phase 2b trial in the United States aims to further evaluate the diagnostic performance of RAD 101, potentially enhancing the company’s positioning in the oncology radiopharmaceutical market.